In patients with a newly detected murmur, but without other signs or symptoms of CVD, TTE should be considered before moderate-risk NCS. (Evidence: Level C，Recommendation: Class Ⅱa)

It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate- to high-risk NCS. (Evidence: Level B，Recommendation: Class Ⅰ)

It is recommended to perform a pre-operative risk assessment, ideally at the same time as the NCS is proposed. (Evidence: Level B，Recommendation: Class Ⅰ)

In all patients scheduled for NCS, an accurate history and clinical examination are recommended. (Evidence: Level C，Recommendation: Class Ⅰ)

In patients with dyspnoea and/or peripheral oedema, an ECG and an NT-proBNP/BNP test is indicated before NCS, unless there is a certain non-cardiac explanation.(Evidence: Level C，Recommendation: Class Ⅰ)

In patients with dyspnoea and/or peripheral oedema and elevated NT-proBNP/BNP, TTE is recommended before NCS. (Evidence: Level C，Recommendation: Class Ⅰ)

If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS. (Evidence: Level C，Recommendation: Class Ⅰ)

In patients with a newly detected murmur and symptoms or signs of CVD, TTE is recommended before NCS. (Evidence: Level C，Recommendation: Class Ⅰ)

In patients who have known CVD, CV risk factors (including age≥65 years), or symptoms suggestive of CVD it is recommended to measure hs-cTn T or hs-cTn I before intermediate- and high-risk NCS, and at 24 h and 48 h afterwards. (Evidence: Level B，Recommendation: Class Ⅰ)

In patients with moderate-to-severe rheumatic MS and symptoms or SPAP＞50 mmHg, valve intervention (percutaneous mitral commissurotomy or surgery) is recommended before elective intermediate- or high-risk NCS. (Evidence: Level C，Recommendation: Class Ⅰ)